A major multicenter randomized controlled trial published in The New England Journal of Medicine has challenged the conventional surgical approach to Chiari I malformation, revealing that adding duraplasty to posterior fossa decompression provides only marginal clinical benefit. The study, led by Dr. John Heiss at the National Institute of Neurological Disorders and Stroke, enrolled patients across multiple medical centers and followed them for 24 months using composite endpoints measuring symptom improvement and radiological changes. Success rates reached 65.3% with duraplasty compared to 63.1% with decompression alone—a difference smaller than many surgeons anticipated. Both approaches demonstrated comparable safety profiles, with serious complications occurring in fewer than 5% of patients. These findings provide evidence-based guidance for surgical decision-making in Chiari I patients with syringomyelia, potentially streamlining treatment protocols and reducing unnecessary procedural complexity.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Major Trial Finds Minimal Benefit of Duraplasty for Chiari I Surgery →
